查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715422

液态切片市场按生物标记、样本、类型、技术、适应症、最终用户和应用划分——2025-2030 年全球预测

Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计液态切片市场规模在 2023 年将达到 60 亿美元，在 2024 年将成长至 67.2 亿美元，在 2030 年将达到 134.4 亿美元，复合年增长率为 12.19%。

主要市场统计数据
基准年2023年 60亿美元
预计年份：2024年 67.2亿美元
预测年份 2030 134.4亿美元
复合年增长率（%） 12.19%

液态切片从根本上重新定义了诊断测试和个人化患者照护的领域。近年来，非侵入性诊断技术的创新正在彻底改变疾病（尤其是癌症）的检测和监测方式。此方法依赖非固态生物组织（主要是血液）的采样和分析，为传统切片检查提供了可行的替代方法。液态切片技术的发展源于其捕获循环生物标誌物的能力，这些标誌物可提供有关疾病病理的即时信息，并能够及时、有针对性的治疗性介入。

科学界对利用这项技术克服传统组织切片检查的局限性、增强早期检测和促进持续监测的兴趣日益浓厚。在研发投入不断增加和精确分析工具整合的推动下，液态切片市场目前正处于临床需求和技术进步的整合阶段。除了在肿瘤学中的应用外，液态切片还迅速扩展到其他医疗保健领域，以提供更全面的诊断解决方案。该分析对当前市场状况进行了深入研究，强调了趋势、细分、区域见解和推动这场技术革命的主要企业。

液态切片格局的变化

受技术进步、法规结构不断发展以及对微创诊断程序的需求不断增长的推动，液态切片市场正在经历快速转型。在过去的几年中，人们已经明显地从传统方法转向提供更高精度、更快週转时间和更广泛适用性的解决方案。高效能定序、数据分析和自动化的进步不仅提高了测试结果的敏感度和特异性，而且使程式更具成本效益。

行业相关人员正在接受这些变化，寻求利用液态切片的能力来捕捉动态遗传和表观遗传变化。这种变化体现在研究机构、技术提供者和医疗保健专业人员之间的积极合作，旨在改善生物标誌物的发现和检验过程。此外，简化的监管途径进一步加速了新工具和新检测方法在临床实践中的引入。随着市场采用率的扩大，竞争格局也不断扩大，从而形成了一个持续创新和整合多领域专业知识至关重要的环境。液态切片的当前势头表明，采用精准医疗作为临床诊断标准实践的趋势更为广泛，最终有助于改善患者的治疗效果并提高整个医疗保健系统的成本效率。

按市场细分的主要市场概况

对液态切片市场的详细细分揭示了支持多种疾病检测和管理方法的复杂结构。核心分析之一是基于生物标记，强调游离DNA、循环性肿瘤细胞、循环肿瘤DNA和细胞外囊泡的重要性。这种基于生物标记的分割不仅突显了多样化的诊断能力，而且突显了每种标记物提供的特定分子见解。按样本类型细分同样重要。该市场已透过多种利用血液和尿液样本的方法进行了探索，既方便又有临床效果。

此外，市场还根据所提供的产品或服务类型进行细分，包括检测试剂套件、仪器和服务。同样重要的是技术细分，依靠先进的平台，例如使用NGS进行多基因平行分析和使用PCR微阵列进行单基因分析。此细分进一步根据适应症区分应用，区分肿瘤学和非肿瘤学适应症。在癌症领域，子分类包括乳癌、结肠癌、肺癌、黑色素瘤和摄护腺癌等常见疾病，每种疾病都需要特定的诊断关注。另一个维度侧重于最终用户环境，从学术和研究中心到临床诊断实验室、医院和医生办公室实验室。最后，应用细分涵盖早期癌症筛检、復发监测、治疗方法选择和治疗监测等过程，所有这些都支持全面的患者管理策略。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球癌症发生率不断上升，需要早期诊断方法
      • 政府支持采用非侵入性诊断工具的措施和政策
    • 限制因素
      • 与循环性肿瘤细胞丰度低和脆弱性有关的担忧
    • 机会
      • 资助液态切片领域的癌症研究扩展
      • 微阵列和次世代定序（NGS）的重要用途
    • 任务
      • 液态切片技术中的资料隐私问题和伦理问题
  • 市场区隔分析
    • 生物标记：cfDNA 在识别基因变异方面的多功能和重要用途
    • 例如：广泛的临床应用和强大的数据支持推动了血液液态生物检体的使用增加
    • 类型：用于早期检测和筛检癌症症状的检测套组的使用演变
    • 技术：使用次世代定序 (NGS) 对多个基因进行平行分析越来越受到青睐，从而产生更高通量的数据
    • 适应症：由于乳癌发生率高，乳癌液态切片检测的需求激增。
    • 最终用户：液态切片检测在临床诊断实验室中的使用量激增
    • 应用：液态切片在早期癌症筛检中的应用呈指数级增长
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章液态切片市场（按生物标记）

  • 介绍
  • 游离DNA
  • 循环性肿瘤细胞
  • 循环肿瘤DNA
  • 细胞外囊泡

第七章液态切片市场（按样本）

  • 介绍
  • 以血液为基础
  • 尿基

第 8 章液态切片市场（按类型）

  • 介绍
  • 检测试剂套件
  • 装置
  • 服务

第九章液态切片市场（按技术）

  • 介绍
  • 使用NGS并行分析多个基因
  • 使用PCR微阵列进行单一基因分析

第 10 章液态切片市场（按适应症）

  • 介绍
  • 癌症适应症
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 黑色素瘤
    • 摄护腺癌
  • 非癌症适应症

第 11 章液态切片市场（按最终用户）

  • 介绍
  • 学术研究中心
  • 临床诊断实验室
  • 医院
  • 医生办公室检查室

第 12 章液态切片市场（按应用）

  • 介绍
  • 早期癌症筛检
  • 復发监测
  • 治疗方法方案
  • 治疗监测

13.美洲液态切片市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太液态切片市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲液态切片市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENCURIX
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43470FC608C8

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023 and is projected to grow to USD 6.72 billion in 2024, with a CAGR of 12.19%, reaching USD 13.44 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 6.00 billion
Estimated Year [2024] USD 6.72 billion
Forecast Year [2030] USD 13.44 billion
CAGR (%) 12.19%

Liquid biopsy has fundamentally redefined the landscape of diagnostic testing and personalized patient care. Over recent years, innovations in non-invasive diagnostics have set the stage for transformative change in how diseases, particularly cancer, are detected and monitored. This method, which relies on sampling and analyzing non-solid biological tissue, primarily blood, offers a viable alternative to traditional surgical biopsies. The evolution of liquid biopsy technology is driven by its ability to capture circulating biomarkers that provide real-time information about the disease state, enabling timely and targeted therapeutic interventions.

The scientific community has shown an increasing interest in leveraging this technique to overcome the limitations of conventional tissue biopsy, enhancing early detection and facilitating ongoing monitoring. With growing investment in research and development and the integration of high-precision analytical tools, the liquid biopsy market now stands at the convergence of clinical need and technological advancement. In addition to its applications in oncology, liquid biopsy is rapidly expanding its footprint into other areas of medicine, enabling more comprehensive diagnostic solutions. This analysis provides an in-depth look into the current state of the market, elucidating the trends, segmentation, regional insights, and major players who are driving this innovation forward.

Transformative Shifts in the Landscape of Liquid Biopsy

The liquid biopsy market is witnessing rapid transformation fueled by advancements in technology, evolving regulatory frameworks, and increasing demand for minimally invasive diagnostic procedures. Over the past few years, there has been a distinct shift away from traditional methods towards solutions that offer greater precision, faster turnaround times, and broader applicability. Improvements in high-throughput sequencing, data analytics, and automation have not only enhanced the sensitivity and specificity of test results but also made the procedures more cost-effective.

Industry stakeholders are embracing these changes as they seek to leverage the ability of liquid biopsies to capture dynamic genetic and epigenetic alterations. This shift is marked by proactive collaborations between research institutions, technology providers, and healthcare practitioners aimed at refining biomarker discovery and validation processes. Moreover, streamlined regulatory pathways have further accelerated the introduction of novel tools and assays into the clinical setting. As market adoption expands, so too does the competitive landscape, leading to an environment where continuous innovation and integration of multi-disciplinary expertise remain essential. The current momentum surrounding liquid biopsy illustrates a broader trend of adopting precision medicine as a standard practice in clinical diagnostics, ultimately contributing to improved patient outcomes and cost efficiencies across healthcare systems.

Key Segmentation Insights for a Nuanced Market Overview

A detailed segmentation of the liquid biopsy market reveals an intricate structure that supports a diversified approach to disease detection and management. One of the core dimensions of the analysis is based on biomarkers, which underscores the importance of Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles. This biomarker-based segmentation not only highlights the varied diagnostic capabilities but also emphasizes the specific molecular insights that each marker provides. Equally important is the segmentation based on sample type. The market is studied across methodologies that utilize Blood Based and Urine Based samples, supporting both convenience and clinical effectiveness.

Furthermore, the market is categorized by the type of products and services offered, encompassing Assay Kits, Instruments, and Services, each playing a unique role in driving diagnostic performance. Equally significant is the segmentation based on technology, which leans on advanced platforms such as Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays. The segmentation further differentiates applications by indication, distinguishing between Cancer Indication and Non-Cancer Indication. In the cancer segment, sub-classifications include prevalent conditions such as Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer, each requiring specific diagnostic attention. Other dimensions focus on end-user environments, ranging from Academic & Research Centers to Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories. Finally, the application segmentation covers processes such as Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring, all of which collectively underpin a comprehensive patient management strategy.

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.

Based on Sample, market is studied across Blood Based and Urine Based.

Based on Type, market is studied across Assay Kits, Instruments, and Services.

Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.

Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.

Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.

Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.

Key Regional Insights Shaping Market Dynamics

Geographical analysis reveals distinctive growth patterns and market dynamics across different regions. In the Americas, high healthcare expenditure and advanced technological adoption in diagnostic practices have fostered rapid market growth and innovation. The region has been instrumental in validating cutting-edge approaches to liquid biopsy, driven by a synergistic ecosystem of research institutions, biotech companies, and regulatory support.

In the combined region of Europe, Middle East & Africa, the market benefits from robust public healthcare systems and collaborative research efforts that bridge technology with clinical practice. Firms in these regions are increasingly investing in the development of assays and platforms tailored to local healthcare needs, thereby enhancing diagnostic access and efficacy. Asia-Pacific stands out as a key growth driver, with emerging economies spearheading investment in healthcare infrastructure and diagnostic technologies. Government initiatives and rapidly expanding insurance coverage are further catalyzing market expansion. Cultural shifts towards early disease detection, combined with increased awareness and adoption of preventive healthcare measures, are expected to propel this region into a leading market segment over the coming years. Such geographical diversity highlights the regional nuances that collectively contribute to the global narrative of the liquid biopsy revolution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Steering Innovation and Competition

The competitive landscape in the liquid biopsy market is characterized by a blend of established industry giants and nimble innovators. Prominent market players such as ANGLE PLC, Bio-Rad Laboratories, Inc., and Bio-Techne Corporation have cemented their roles by continuously investing in new technologies and expanding their product portfolios. Biocartis NV and Danaher Corporation, along with DiaCarta, Inc. and Dxcover Limited, are also pivotal in driving forward the diagnostic capabilities of liquid biopsy through strategic collaborations and cutting-edge research.

Epic Sciences Inc. and Exact Sciences Corporation have distinguished themselves by developing assays that offer high sensitivity and specificity, thereby setting benchmarks for clinical outcomes. F. Hoffmann-La Roche Ltd. and GENCURIX have leveraged their extensive experience in diagnostics to integrate liquid biopsy into broader therapeutic management frameworks. Companies such as Guardant Health, Inc. and Illumina, Inc. are renowned for their state-of-the-art sequencing technologies, which have significantly advanced the liquid biopsy field. The market is further enriched by contributions from Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, and Lucence Health Inc., whose innovative solutions drive process improvements in sample analysis. LungLife AI, Inc. and MDxHealth SA are actively involved in the development of artificial intelligence tools that further enhance diagnostic precision, while players like Menarini Silicon Biosystems SpA, Merck KGaA, and Myriad Genetics, Inc. maintain strong research pipelines. Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc. round out the competitive spectrum by contributing critical research, robust analytical frameworks, and dynamic market strategies that collectively propel the industry toward sustained innovation and global influence.

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENCURIX, Guardant Health, Inc., Illumina, Inc., Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to invest in furthering diagnostic research and technological innovation while integrating cross-functional collaboration with clinical practitioners to boost validation studies. Active engagement in strategic partnerships with both academia and technology developers will ensure that emerging trends and regulatory changes are effectively leveraged to maintain competitive advantage. Emphasis should be placed on diversifying product suites to include next-generation sequencing platforms and advanced amplification tools that cater to evolving market needs. Furthermore, leaders must continuously evaluate supply chain efficiencies and streamline operational processes to reduce time-to-market for new diagnostic tools. Adoption of digital analytics and data management solutions can also play a pivotal role in optimizing clinical decision-making and improving patient outcomes. By staying abreast of technological advancements and regional market trends, companies can secure a leading position in a rapidly evolving landscape.

Conclusion: Charting the Course for Future Success

In summary, the liquid biopsy market represents a dynamic intersection of technological innovation and clinical application. The comprehensive insights provided, categorized by biomarkers, sample types, product offerings, technologies, indications, end-user environments, and applications, underscore the evolving nature of diagnostics in the modern medical landscape. Regional and competitive analyses further highlight that success in this arena depends on the ability to integrate cutting-edge science with strategic execution. As the market continues to mature, ongoing innovation and adaptive strategies will be crucial in meeting the challenges of evolving disease profiles and regulatory environments. This analysis reaffirms that a proactive, research-driven approach remains central to leveraging the full potential of liquid biopsy applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer worldwide necessitating early diagnosis methods
      • 5.1.1.2. Supportive government initiatives and policies for the adoption of non-invasive diagnostic tools
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with low abundance and fragile nature of the circulating tumor cells
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of funding to expand cancer research in the field of liquid biopsy
      • 5.1.3.2. Significant use of microarrays and next-generation sequencing (NGS)
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy concerns and ethical issues in liquid biopsy technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
    • 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
    • 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
    • 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
    • 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
    • 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
    • 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liquid Biopsy Market, by Biomarkers

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Circulating Tumor DNA
  • 6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

  • 7.1. Introduction
  • 7.2. Blood Based
  • 7.3. Urine Based

8. Liquid Biopsy Market, by Type

  • 8.1. Introduction
  • 8.2. Assay Kits
  • 8.3. Instruments
  • 8.4. Services

9. Liquid Biopsy Market, by Technology

  • 9.1. Introduction
  • 9.2. Multi-gene Parallel Analysis using NGS
  • 9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

  • 10.1. Introduction
  • 10.2. Cancer Indication
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Melanoma
    • 10.2.5. Prostate Cancer
  • 10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic & Research Centers
  • 11.3. Clinical Diagnostic Laboratories
  • 11.4. Hospitals
  • 11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

  • 12.1. Introduction
  • 12.2. Early Cancer Screening
  • 12.3. Recurrence Monitoring
  • 12.4. Therapy Selection
  • 12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Liquid Biopsy Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Mayo Clinic and Lucence join forces to expand global liquid biopsy access
    • 16.3.2. PanGIA Biotech and Canary Oncoceutics partner to pioneer an AI-integrated urine-based liquid biopsy
    • 16.3.3. QIAGEN expands liquid biopsy automation portfolio
    • 16.3.4. Strand Life Sciences launches liquid biopsy test for improved cancer diagnosis
    • 16.3.5. Novigenix unveils an AI-powered multimodal liquid biopsy approach that integrates cfDNA analysis and mRNA immune profiling
    • 16.3.6. SOPHiA GENETICS partners with the European Liquid Biopsy Society to advance decentralized liquid biopsy solutions
    • 16.3.7. Hitachi High-Tech and Gencurix forge strategic partnership to revolutionize cancer molecular diagnostics through advanced liquid biopsy and digital reporting for personalized treatment decisions
    • 16.3.8. Personalis and Tempus partner to advance precision liquid biopsy diagnostics
    • 16.3.9. Renovaro Biosciences to acquire Cyclomics to transform liquid biopsy technology
    • 16.3.10. Myriad Genetics expands its oncology portfolio by acquiring Precise Tumor and Precise Liquid assays from Intermountain Precision Genomics
    • 16.3.11. Veracyte strengthens liquid biopsy platform with C2i Genomics acquisition
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. F. Hoffmann-La Roche Ltd.
    • 16.4.2. Illumina, Inc.
    • 16.4.3. QIAGEN N.V.
    • 16.4.4. Guardant Health, Inc.

Companies Mentioned

  • 1. ANGLE PLC
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Bio-Techne Corporation
  • 4. Biocartis NV
  • 5. Danaher Corporation
  • 6. DiaCarta, Inc.
  • 7. Dxcover Limited
  • 8. Epic Sciences Inc.
  • 9. Exact Sciences Corporation
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GENCURIX
  • 12. Guardant Health, Inc.
  • 13. Illumina, Inc.
  • 14. Labcorp Holdings Inc.
  • 15. Laboratory Dr. med. Pachmann
  • 16. Lucence Health Inc.
  • 17. LungLife AI, Inc.
  • 18. MDxHealth SA
  • 19. Menarini Silicon Biosystems SpA
  • 20. Merck KGaA
  • 21. Myriad Genetics, Inc.
  • 22. Natera, Inc.
  • 23. NeoGenomics Laboratories, Inc.
  • 24. OncoDNA SA
  • 25. PerkinElmer, Inc.
  • 26. Personalis, Inc.
  • 27. QIAGEN N.V.
  • 28. SAGA Diagnostics AB
  • 29. Strand Life Sciences Pvt Ltd.
  • 30. Sysmex Corporation
  • 31. Tempus AI, Inc.
  • 32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. LIQUID BIOPSY MARKET MULTI-CURRENCY
  • FIGURE 2. LIQUID BIOPSY MARKET MULTI-LANGUAGE
  • FIGURE 3. LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 4. LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 372. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 373. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 374. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023